Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Dynasty Wealth Management LLC

Dynasty Wealth Management LLC raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 84.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,273 shares of the medical equipment provider’s stock after buying an additional 3,330 shares during the period. Dynasty Wealth Management LLC’s holdings in Hologic were worth $524,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. General Partner Inc. acquired a new stake in shares of Hologic during the 4th quarter worth about $26,000. Groupama Asset Managment raised its holdings in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares in the last quarter. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Finally, Covestor Ltd raised its stake in Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on HOLX shares. Raymond James reiterated an “outperform” rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Monday, February 3rd. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $85.77.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.88% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $63.38 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $84.67. The stock has a market cap of $14.22 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The firm’s fifty day simple moving average is $69.16 and its 200-day simple moving average is $75.97.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.